Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2005

01-01-2005 | Report

Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory

Authors: Kathy D. Miller, Sharon E. Soule, Cynthia Calley, Robert E. Emerson, Gary D. Hutchins, Kenyon Kopecky, Sunil Badve, AnnaMaria Storniolo, Robert Goulet, George W. Sledge Jr

Published in: Breast Cancer Research and Treatment | Issue 2/2005

Login to get access
Metadata
Title
Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory
Authors
Kathy D. Miller
Sharon E. Soule
Cynthia Calley
Robert E. Emerson
Gary D. Hutchins
Kenyon Kopecky
Sunil Badve
AnnaMaria Storniolo
Robert Goulet
George W. Sledge Jr
Publication date
01-01-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-2044-y

Other articles of this Issue 2/2005

Breast Cancer Research and Treatment 2/2005 Go to the issue

Report

Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status

Report

cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion

Report

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

Report

Ultrasound criteria for ductal invasive breast cancer are modified by age, tumor size, and axillary lymph node status

Report

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response

Report

Automatic ultrasound segmentation and morphology based diagnosis of solid breast tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits